Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|October 8, 2014

Change is Afoot at CPhI

New investments, expansions, and company rebranding are discussed at CPhI.

CPhI is buzzing with talk of new investments, expansions, and company rebranding. For instance, in September 2014 SGS completed a new lab in Carson, California that will offer microbioligical testing and bioanalytical services to biotech companies in the region. The company is also constructing a new, state-of-the-art QC lab outside of Paris and is expanding its laboratory in Shanghai with no bioanalytical capabilities, including cytotoxicity and endotoxin testing, cell-based assays, and others.

Hovione, meanwhile, has changed its logo to reflect the fact that it now has capabilities in both chemistry and biotechnology. The company is celebrating both 10 years of commercial spray drying and the largest installed capacity for commercial GMP spray drying. Hovione will also be expanding its Hovione New Jersey manufacturing site, which has capabilities in cryogenic chemistry, hydrogenation, fluorination, and the production of highly potent APIs.

To reflect its responsiveness to customer needs, Dr. Reddy's CPS has introduced a new logo and tag line -"The Power of Now." In addition, to ensure that it is aligned with customer needs,the company has hired a new head of R&D and a new North American Manager and appointed and created a new business development position in Asia. Key technologies for Dr. Reddy's CPS include chiral chemistry, pegylation technology, continuous processing, and the production of steroids and highly potent compounds, including drug substances and formulated products at both development and commercial scales.


Related to this article

The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.